Causality between Diabetes and MN: Mendelian randomization and meta-analysis

Zhihang Su^{1,+}, Ziqi Luo^{2,+}, Di Wu¹, Wen Liu¹, Wangyang Li¹, Zheng Yin¹, Rui Xue¹, Liling Wu¹, Yuan Cheng¹, Qijun Wan^{*}

- ³ ¹ Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
- 4 Shenzhen University, Shenzhen, China
- ² Department of Endocrinology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
 Shenzhen University, Shenzhen, China
- 7 *** Correspondence:**
- 8 Corresponding Author: Qijun Wan (Email: yiyuan2224@sina.com)
- 9

Keywords: Diabetes, Insulin use, Membranous nephropathy, Mendelian randomization, Meta analysis, Genome-wide association studies (GWAS).

12 Abstract

13 Background:

- 14 Membranous nephropathy (MN) has not yet been fully elucidated regarding its relationship with
- 15 Type I and II Diabetes. This study aims to evaluate the causal effect of multiple types of diabetes and
- 16 MN by summarizing the evidence from the Mendelian randomization (MR) study.

17 Methods:

- 18 The statistical data for MN was obtained from a GWAS study encompassing 7,979 individuals.
- 19 Regarding diabetes, fasting glucose, fasting insulin, and HbA1C data, we accessed the UK-Biobank,
- 20 within family GWAS consortium, MAGIC, Finnish database, MRC-IEU, and Neale Lab, which
- 21 provided sample sizes ranging from 17,724 to 298,957. As a primary method in this MR analysis, we
- 22 employed the Inverse Variance Weighted (IVW), Weighted Median, Weighted mode, MR-Egger,
- 23 Mendelian randomization pleiotropy residual sum, and outlier (MR-PRESSO) and Leave-one-out
- 24 sensitivity test. Reverse MR analysis was utilized to investigate whether MN affects Diabetes. Meta-
- analysis was applied to combine study-specific estimates.

26 **Results** :

- 27 It has been determined that type 2 diabetes, gestational diabetes, type 1 diabetes with or without
- 28 complications, maternal diabetes, and insulin use pose a risk to MN. Based on the genetic prediction,
- 29 fasting insulin, fasting blood glucose, and HbA1c levels were not associated with the risk of MN. No
- 30 heterogeneity, horizontal pleiotropy, or reverse causal relationships were found. The meta-analysis
- 31 results further validated the accuracy.

32 **Conclusions:**

33 The MR analysis revealed the association between MN and various subtypes of diabetes. This study

34 has provided a deeper understanding of the pathogenic mechanisms connecting MN and diabetes.

Introduction 35 1

36 Membranous nephropathy (MN), the most common etiology in adult nephrotic syndrome, is an 37 immune-related disease(1). Approximately 80% of patients cannot identify a specific cause and are 38 referred to as primary MN. The formation of immune complexes in the mesangial area, typically 39 comprising immunoglobulin G (IgG), associated antigens, and complement components, including 40 the membrane attack complex (MAC), results in substantial thickening of the glomerular capillary 41 walls(2). Immune dysregulation resulting from this immune conflict disrupts the structural integrity 42 of podocytes, leading to significant proteinuria. Spontaneous complete remission rates of untreated 43 MN have been reported to range from 20% to 30%, and advancements have been achieved in 44 utilising immunosuppressive drugs to manage MN. However, around 10% of patients with MN 45 eventually develop end-stage renal disease (ESRD), and within a 10-year timeframe, 40-50% of

46 individuals with nephrotic syndrome encounter kidney failure.

47 Diabetes is an increasingly severe global public health issue, with its prevalence increasing year by 48 year. As of 2019, approximately 463 million adults (one in ten) worldwide have diabetes, of which 49 half remain undiagnosed(3). In addition, diabetes in young people is also on the rise. Type 1 diabetes 50 in childhood and type 2 diabetes in adolescence are both increasing. The medical costs associated 51 with diabetes and its complications are incalculable(4). Diabetic nephropathy (DN) is a common 52 complication of diabetes. It has become a significant cause of chronic kidney disease (CKD) and end-53 stage renal disease (ESRD) with the increasing prevalence of diabetes(5). In the past, the diagnosis of 54 diabetic nephropathy mainly relied on clinical diagnosis(6). With the development of renal biopsy 55 techniques, it has been found that many patients diagnosed clinically with DN may have non-diabetic 56 renal disease (NDRD)(7). This disease may exist alone or coexist with DN. Early detection of non-57 diabetic renal disease (NDRD) has become critical in our clinical practice. Membranous nephropathy 58 (MN) is a common cause of primary glomerular disease in diabetic patients(8). DN and MN can 59 manifest as proteinuria and impaired renal function, which are difficult to distinguish without renal 60 biopsy(9). Several studies have found that compared with DN patients, NDRD or DN+NDRD patients show significant improvement in proteinuria and renal function after receiving systemic 61 62 treatment with glucocorticoids, immunosuppressants, antihypertensives, and lipid-lowering 63 drugs(10). However, for DN patients, the use of steroids and other immunosuppressive drugs (used to 64 treat MN) can worsen glycemic control and increase the risk of infection in diabetic patients. Although membranous nephropathy is a commonly occurring primary glomerular disease in non-65 66 diabetic individuals, data on its natural progression, treatment, and outcomes in diabetic patients are

67 limited.

68 Previous magnetic resonance (MR) studies have firmly established a causal link between diabetes 69 and a range of systemic diseases, encompassing gastrointestinal disease, carcinoma psychiatric 70 disorders and so on(11-13). Nevertheless, a comprehensive overview of the association between 71 diabetes and MN remains elusive, hindering our comprehension of severe kidney diseases associated 72 with diabetes. Consequently, we conducted an MR analysis to evaluate the causal relationship 73 between diabetes phenotypes and MN, considering this challenge. MR is an analytical method to 74 infer causal relationships between exposures and outcomes(14). It utilizes instrumental variables, 75 which are single nucleotide polymorphisms (SNPs) identified from genome-wide association studies 76 (GWAS)(15). These SNPs are widely employed as instrumental variables (IVs) because their alleles 77 are randomly assigned and independent of confounding factors such as gender and age and are

- value of the outcome (e.g., the disease itself). Compared to traditional observational studies,
- 79 MR methods effectively address issues related to confounding factors and reverse causality. In this
- 80 study, we conducted MR analysis using phenotype data for diabetes phenotypes and MN obtained
- 81 from large-scale, openly accessible GWAS data.

82 2 Data source

83 We extracted the MR analysis data from the IEU Open GWAS database, which predominantly

- 84 comprises publicly available GWAS summary datasets(Figure 1). The statistical data for
- 85 membranous nephropathy (MN) was obtained from a GWAS study encompassing 7,979 individuals,
- of which 2,150 were cases of primary MN and 5,829 served as controls(8). These individuals were
- 87 drawn from five European cohorts. The diagnosis of idiopathic membranous nephropathy cases was
- confirmed through the gold standard diagnostic method of renal biopsy. Notably, secondary factors
 such as patients with hepatitis B virus infection, drug-induced causes, and malignant tumours were
- 90 excluded from the analysis. Regarding diabetes, fasting glucose, fasting insulin and HbA1C data, we
- 91 accessed the UK-Biobank, Within family GWAS consortium, MAGIC, Finnish database, MRC-IEU,
- 92 and Neale Lab, which provided sample sizes ranging from 17,724 to 298,957(16–20). It is essential
- 93 to mention that all the databases above predominantly comprise individuals of European descent.

94 **3** Methods and materials

95 **3.1 Selections of Instrument Variants**

- 96 The instrument variants (IVs) utilized in this MR study must adhere to three fundamental
- 97 assumptions (Figure 1):
- 98 (i) IVs should demonstrate strong associations with diabetes phenotypes. IVs with an F statistic less 99 than 10 [F = $(\beta / SE)^2$] are considered weak and therefore excluded.
- 100 (ii) IVs need to be independent. IVs associated with diabetes phenotypes were identified at a
- 101 genome-wide significance level ($P < 5 \times 10^{-8}$). IVs in high linkage disequilibrium (r²) were identified
- 102 using a European reference panel (1000 gene project)(21), with exclusion criteria of $r^2 > 0.001$ or
- 103 within 10,000 kb.
- 104 (iii) IVs must be unrelated to the MN, influencing the outcome solely through indirect diabetes traits.
- 105 Additionally, potential confounding factors that could impact the association between diabetes traits
- and MN were accounted for. These confounders include hepatitis B, hepatitis C, malignancies, and
- 107 medications (such as non-steroidal anti-inflammatory drugs, gold compounds, d-penicillamine,
- 108 bucillamine, and cyclosporine). Any IVs that could potentially act as confounders were removed.

109 **3.2 Mendelian randomization**

- 110 To ensure the robustness of our findings, we employed a range of methods in the MR analysis,
- 111 including Inverse variance weighted (IVW), MR Egger, Weighted median, Weighted mode,
- 112 Maximum likelihood, Constrained maximum likelihood (CML), and Penalized weighted median.
- 113 Among these approaches, IVW analysis emerges as the most effective MR analysis when genetic
- 114 instrument pleiotropy is absent, and the sample size is sufficiently large(22). IVW estimation
- 115 consistently provides reliable and close-to-true effect estimates. Consequently, we designated IVW as
- the primary MR method. In instances where heterogeneity analysis yielded significant results (P < 1000
- 117 0.05), we employed the IVW random effects model. The MR Egger method was utilized to examine

- directional pleiotropy and causal associations, assuming the invalidity of all SNPs as instruments(23).
- 119 Weighted median analysis was employed when at least half of the SNPs had valid instruments(24).
- 120 CML evaluated population-wide overlap by maximizing the likelihood function, resulting in lower
- standard errors. The Penalized weighted median estimator was also employed as a supplementary
- method, modifying the standard weighted median MR. Causal estimate results from both primary and
- supplementary MR analyses were visualized using scatter plots, while funnel plots were used to deniat the distribution of individual SNB affacts. The MR analysis results are presented in the
- depict the distribution of individual SNP effects. The MR analysis results are presented in the
- 125 accompanying table.

126 **3.3 Sensitivity analysis**

- 127 The sensitivity analysis comprises heterogeneity tests, pleiotropy tests, and leave-one-out analysis.
- 128 Our objective is to ensure that the significant results of the MR do not demonstrate heterogeneity or
- 129 horizontal pleiotropy in the sensitivity analysis. The heterogeneity of SNPs in each analysis is
- assessed using Cochran's Q statistic, with P > 0.05 indicating the absence of heterogeneity in the MR
- results(25). Horizontal pleiotropy may result in false positive findings when instrumental variables
- are linked to multiple independent phenotypic effects. The MR Egger intercept test assesses
- horizontal pleiotropy, with P > 0.05 indicating the absence of evidence for horizontal pleiotropy(23).
- 134 Leave-one-out analysis entails the sequential removal of instrumental variables for reanalysis to
- evaluate the potential bias of individual SNPs on causal estimates. Since multiple databases are
- 136 utilized for specific subtypes of diabetes, we will acquire multiple MR results. Since multiple
- databases are used for certain subtypes of diabetes, we will acquire multiple MR results. In cases
- 138 where two or more MR estimates for the same outcome derived from non-overlapping samples exist,
- 139 meta-analysis will be employed to derive a pooled estimate.

140 **3.4 Reverse Mendelian randomization analysis**

- 141 To avoid directional confounders, we will consider MN as the exposure and various subtypes of
- 142 diabetes as the outcomes for a subsequent round of MR analysis.

143 **3.5 Meta-analysis**

- 144 Due to the duplication of diabetes-related phenotype databases, we conducted MR analysis on
- 145 phenotypes with multiple databases and obtained various results. We then performed a meta-analysis
- 146 of the above results using a random-effects model(26).

147 **4 Results**

148 The MR analysis revealed significant associations between type 1, type 2, maternal, and gestational 149 diabetes and insulin use in diabetic patients with an elevated risk of MN(Figure 2 and 3, Supplement 150 Tables 1-4). We also found that the genetic prediction of fasting insulin, fasting blood glucose, and HbA1c levels were not associated with the risk of MN(Supplement Tables 5-7). An increment of one 151 152 standard deviation (SD) in the genetic prediction of diverse diabetes-related phenotypes is associated 153 with a higher odds ratio (OR) for MN. The scatter plots depict the causal relationships and effect 154 sizes for each MR method. The funnel plots exhibit a well-balanced distribution of SNP effects. 155 Leave-one-out analysis identified no influential outliers impacting the final estimates, and the genetic prediction-based causal effects of distinct diabetes subtypes on MN remained consistent with the 156 157 initial MR analysis even after sequentially removing individual SNPs. This indicates the stability and 158 robustness of our MR study. No evidence of horizontal pleiotropy or heterogeneity was observed (P 159 > 0.05), suggesting that other potential confounding factors are unlikely to introduce bias in our MR

160 study. In the reverse MR analysis, we did not find any evidence of reverse causality(Supplement

161 Table 8). The meta-analysis results of diverse phenotypes across multiple databases, employing a

162 random-effects model, exhibited statistical significance across the board, corroborating our MR

analysis findings. This provides further confirmation of the potential heightened risk of MN

associated with various diabetes-related phenotypes.

165 **5 Discussion**

166 The causal relationship between diabetes and MN remains a complex and multifaceted subject. In

recent years, the advancement of medical research has led to a gradual recognition of the intimate association between diabetes and kidney diseases, particularly MN. This article aims to delve deeply

168 association between diabetes and kidney diseases, particularly MN. This article aims to derve de 169 into the causal link between diabetes and MN, aiming to enhance public awareness and

170 comprehension of these diseases. This study marks the first attempt to integrate GWAS data from

extensive cohorts, utilizing multi-sample MR analysis and meta-analysis to assess the causal

relationship between various diabetes-related phenotypes and MN. Based on gene prediction, our

173 findings ultimately revealed that type 1 diabetes, type 2 diabetes, gestational diabetes, and insulin use

in diabetic patients in diabetic patients were significantly associated with an elevated risk of MN.

175 Sensitivity analysis further corroborated the positive causal relationship between these phenotypes

176 and MN.

177 Diabetes is a metabolic disease marked by persistently high blood glucose levels, potentially linked

178 to genetic predisposition, environmental factors, autoimmune responses, and other contributing

elements. MN, on the other hand, is a glomerular disorder associated with immune complexes. Its

180 primary manifestation is the deposition of these immune complexes on the epithelial side of the

181 glomerular capillary wall, often accompanied by widespread thickening of the basement membrane.

182 Our study revealed a positive correlation between MN and various diabetes types, including type 1,

type 2, gestational diabetes, and insulin usage among diabetes patients. Furthermore, Mendelian

184 randomization studies provide evidence for a causal linkage between genetic predisposition to

185 diabetes and an elevated risk of MN. However, our analysis indicated that genetically predicted

186 levels of fasting insulin, fasting glucose, and glycosylated hemoglobin did not correlate with the risk

187 of MN, suggesting that the association between diabetes subtypes and MN is not primarily mediated

by glucose dysregulation. Discovering a link between impaired glucose homeostasis and

189 gastrointestinal diseases holds potential clinical significance. This suggests that apart from managing 190 type 2 diabetes, pharmacological or lifestyle interventions aimed at decreasing circulating glucose

type 2 diabetes, pharmacological or lifestyle interventions aimed at decreasing circulating glucose
 levels and fasting insulin levels could potentially contribute to preventing gastrointestinal diseases.

191 levels and fasting insulin levels could potentially contribute to preventing gastrointestinal disease

192 Numerous studies have consistently demonstrated that diabetes mellitus serves as a primary etiology 193 of kidney disease. Among patients diagnosed with diabetes, approximately 30% to 40% develop 194 kidney disease, with MN being a notable manifestation. However, our analysis indicated that the association between diabetes and MN might not be mediated by glycemic dysregulation but rather by 195 196 other pathophysiological mechanisms. For instance, the immune system function of diabetic patients 197 may be compromised, leading to the deposition of immune complexes on the epithelial side of the 198 glomerular capillary wall, thereby precipitating MN(27). In addition, the incidence of insulin 199 resistance (IR) is continuously increasing in T1DM, T2DM, and gestational diabetes, especially in 200 overweight individuals and patients treated with insulin(28). IR can activate the complement system 201 to induce membranous nephropathy (29). On the other hand, diabetes can cause metabolic disorders

such as glucose, protein, fat, water, and electrolytes, promoting inflammation. Lipid accumulation
 can damage podocytes (a structure and function crucial for maintaining the glomerular filtration

- barrier of the glomerulus) and induce podocyte degeneration and foot process effacement(30).
- 205 Podocyte apoptosis is a critical process in the development of MN (30). Moreover, chronic
- 206 inflammation, including C-reactive protein, mononuclear chemotactic protein-1, interleukin 8, etc,
- 207 caused by diabetes can stimulate the body to secrete various inflammatory factors, exacerbating
- 208 kidney damage and glomerular sclerosis(31).
- 209 The causal link between diabetes and MN is well-established, yet the mechanism underlying this
- 210 relationship remains elusive. Current research has yet to fully elucidate the intricate pathways
- through which diabetes triggers the entire process of MN, leaving this area ripe for further
- exploration.
- 213 It is crucial to acknowledge that, according to genetic predictions, MN does not elevate the risk of
- 214 various diabetes types. Although MN may result in impaired renal function, it is not directly
- 215 implicated in the onset of diabetes. Instead, the occurrence of diabetes is influenced by a multitude of
- 216 factors, including heredity, environmental conditions, and autoimmunity. In contrast, MN primarily
- represents a kidney disease that may be induced by diabetes. Consequently, for diabetic patients, the
- 218 prevention and management of MN are paramount. The risk of MN can be significantly mitigated by
- 219 regulating key parameters such as blood sugar, blood pressure, and blood lipids. Furthermore, for
- 220 patients who have already developed MN, it is imperative to adopt proactive treatment strategies to
- decelerate the progression of the disease and safeguard renal function.
- 222 This study exhibits numerous strengths. Chief among them is the utilization of the MR methodology,
- 223 which significantly mitigates the potential for confounding and reverse causality biases. By
- 224 leveraging summary-level data from extensive genetic studies conducted in European populations,
- 225 our findings are unlikely to be skewed by population structure biases. Furthermore, estimating these
- associations across independent data sources and their subsequent combination through meta-analysis
- 227 enhances the statistical power and the robustness of our research outcomes.
- 228 We must also acknowledge several limitations. Firstly, given that this is a non-linear MR analysis,
- 229 we cannot assess the non-linear association between diabetes and MN using aggregate-level data.
- 230 Moreover, we cannot discount the possibility that diabetes-related SNPs may affect MN through
- alternative causal pathways. Notably, while additional MR analysis results, such as Weighted
- median, Weighted mode, and MR-Egger, no longer exhibit statistically significant associations
 observed in the primary analysis, this could be attributed to a reduction in method efficacy.
- 235 observed in the primary analysis, this could be attributed to a reduction in method efficacy.
 234 Nevertheless, we rely on IVW, the primary MR method, to observe the direction of these
- associations, thus supporting the consistency of our findings. Additionally, sensitivity analysis was
- conducted to validate the consistency of our results further, revealing that our findings are mainly
- unaffected by heterogeneity and horizontal pleiotropy. Secondly, if the dichotomy of continuous risk
- 238 factors primarily defines diabetes, the MR analysis of diabetes as an exposed binary phenotype may
- introduce biases due to the exclusion of restrictive assumptions. However, it is essential to note that
- the threshold of continuous biomarkers does not solely define diabetes; it can also be determined by
 ICD codes, drug usage, self-reports, or the threshold of HbA1c and blood glucose levels, as
- employed in this study. Thirdly, our findings reveal no significant impact of fasting blood glucose,
- fasting insulin, and HbA1c levels on MN. This observation suggests that the association between
- 244 diabetes mellitus of various types and MN is not primarily mediated by glucose dysregulation or
- insulin resistance. Notably, most patients in our study had a long-standing diagnosis of diabetes
- symptoms. These markers alone are clinically inadequate to assess pancreatic function, necessitating
- 247 further evaluation. Consequently, our data imply that diabetes-induced MN may have alternative
- 248 underlying mechanisms. Fourth, despite these findings, the odds ratio (OR) obtained from our MR

- 249 analysis of diabetes remains unexplained by the direct exposure unit, as previously reported in
- studies. This limitation may hinder directly comparing our research outcomes with the magnitude
- 251 reported in observational studies. Fifth, SNPs related to diabetes were sourced from the general
- 252 population, whereas SNPs about blood glucose traits were derived from a population free of diabetes
- 253 diagnosis. Consequently, even if diabetic patients are included in the outcome data, the extrapolation
- of the identified blood glucose traits to the entire population or specifically to diabetic patients
- remains to be validated in future investigations. Sixth, the exclusive inclusion of European
- 256 populations in this study restricts the generality of the findings to other ethnic groups, such as those
- 257 in Asia and Africa. Seventh, discrepancies between genetic scoring and clinical diagnosis of diabetes
- 258 may give rise to potential misclassification of cases.
- 259 In our study, we observed a correlation between the genetic predisposition to diverse forms of
- 260 diabetes and an elevated risk of MN. Notably, fasting blood glucose levels, fasting insulin
- 261 concentrations, and HbA1c markers did not significantly influence the risk of MN. Furthermore,
- diabetes appears to be a contributory factor in the emergence and progression of MN, which serves as
- a manifestation of diabetic kidney disease. The profound comprehension and exploration of this
- intricate relationship hold immense importance in preventing and managing diabetes and its
- associated complications. Additionally, enhancing public knowledge and understanding regarding these diseases is paramount to improving the overall health of individuals. It underscores the vital
- role of early screening and renal disease prevention among diabetic patients.
- 268 6 Conflict of Interest
- 269 No conflict of interest.
- 270 **7 Funding**
- Shenzhen Key Medical Discipline Construction Fund (SZXK009) and Shenzhen Sanming project
 (SZSM202211013).
- 273 8 Acknowledgments
- 274 Thank you to all the contributors of the publicly available databases used in this study.
- 275 9 Data Availability Statement
- 276 All data are uploaded as supplementary materials.

277 **10 Reference styles**

- Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017 Jun
 7;12(6):983–97.
- 280 2. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy.
 281 Nat Rev Dis Primer. 2021 Sep 30;7(1):69.
- 282 3. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF
 283 Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes
- 284 Res Clin Pract. 2018 Apr;138:271–81.

Tuttle KR, Jones CR, Daratha KB, Koyama AK, Nicholas SB, Alicic RZ, et al. Incidence of
Chronic Kidney Disease among Adults with Diabetes, 2015-2020. N Engl J Med. 2022 Oct
13;387(15):1430–1.

288 5. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical
289 catastrophe of worldwide dimensions. Am J Kidney Dis Off J Natl Kidney Found. 1999
290 Nov;34(5):795–808.

Liew A, Bavanandan S, Prasad N, Wong MG, Chang JM, Eiam-Ong S, et al. Asian Pacific
Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease - An Executive
Summary. Nephrol Carlton Vic. 2020 Nov;25(11):809–17.

Huang F, Yang Q, Chen L, Tang S, Liu W, Yu X. Renal pathological change in patients with
type 2 diabetes is not always diabetic nephropathy: a report of 52 cases. Clin Nephrol. 2007
May;67(5):293–7.

297 8. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. The genetic architecture of
298 membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun. 2020
299 Mar 30;11(1):1600.

300 9. Zhang W, Liu X, Dong Z, Wang Q, Pei Z, Chen Y, et al. New Diagnostic Model for the
301 Differentiation of Diabetic Nephropathy From Non-Diabetic Nephropathy in Chinese Patients. Front
302 Endocrinol. 2022;13:913021.

Radhakrishnan Y, Zand L, Sethi S, Fervenza FC. Membranous nephropathy treatment
standard. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2024 Feb
28;39(3):403–13.

Chen J, Yuan S, Fu T, Ruan X, Qiao J, Wang X, et al. Gastrointestinal Consequences of Type
Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study.
Diabetes Care. 2023 Feb 17;46(4):828–35.

309 12. Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, et al. Diabetes and
310 cancer risk: A Mendelian randomization study. Int J Cancer. 2020 Feb 1;146(3):712–9.

311 13. Tao H, Fan S, Zhu T, You L, Zheng D, Yan L, et al. Psychiatric disorders and Type 2

diabetes mellitus: A bidirectional Mendelian randomization. Eur J Clin Invest. 2023
Mar;53(3):e13893.

Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian
randomization analysis. Brain J Neurol. 2023 Aug 1;146(8):3364–72.

Su Z, Wan Q. Potential therapeutic targets for Membranous Nephropathy: proteome-wide
 Mendelian randomization and colocalization analysis. Front Immunol. 2024 Feb 21;15:1342912.

318 16. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, et al. A genome-

319 wide approach accounting for body mass index identifies genetic variants influencing fasting

320 glycemic traits and insulin resistance. Nat Genet. 2012 May 13;44(6):659–69.

321 17. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale
 322 association analyses identify new loci influencing glycemic traits and provide insight into the

323 underlying biological pathways. Nat Genet. 2012 Sep;44(9):991–1005.

Bupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New
genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat
Genet. 2010 Feb;42(2):105–16.

327 19. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10
328 genomic loci influence hemoglobin A□(C) levels via glycemic and nonglycemic pathways. Diabetes.
329 2010 Dec;59(12):3229–39.

Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of
35 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021 Feb;53(2):185–94.

Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-coverage
whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. Cell.
2022 Sep 1;185(18):3426-3440.e19.

Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, EPIC- InterAct
Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification
of causal risk factors. Eur J Epidemiol. 2015 Jul;30(7):543–52.

Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015 Apr;44(2):512–
25.

341 24. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
342 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
343 Epidemiol. 2016 May;40(4):304–14.

Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
genetic variants using summarized data. Genet Epidemiol. 2013 Nov;37(7):658–65.

- Xu S, Li X, Zhang S, Qi C, Zhang Z, Ma R, et al. Oxidative stress gene expression, DNA
 methylation, and gut microbiota interaction trigger Crohn's disease: a multi-omics Mendelian
 randomization study. BMC Med. 2023 May 11;21(1):179.
- Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in
 Type 2 Diabetes Mellitus. J Diabetes Res. 2018;2018:7457269.
- 251 28. Petrelli A, Giovenzana A, Insalaco V, Phillips BE, Pietropaolo M, Giannoukakis N.
- Autoimmune Inflammation and Insulin Resistance: Hallmarks So Far and Yet So Close to Explain
 Diabetes Endotypes. Curr Diab Rep. 2021 Dec 13;21(12):54.
- Xin Y, Hertle E, van der Kallen CJH, Schalkwijk CG, Stehouwer CDA, van Greevenbroek
 MMJ. Complement C3 and C4, but not their regulators or activated products, are associated with
 incident metabolic syndrome: the CODAM study. Endocrine. 2018 Dec;62(3):617–27.

- 357 30. Sun Y, Cui S, Hou Y, Yi F. The Updates of Podocyte Lipid Metabolism in Proteinuric
- 358 Kidney Disease. Kidney Dis Basel Switz. 2021 Nov;7(6):438–51.
- 359 31. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical
- 360 Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with
- 361 Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. Int J Mol Sci. 2021 Aug
- 362 26;22(17):9221.
- 363
- 364 Figure legends
- 365 Figure 1: The flowchart demonstrates the experimental design of this study.
- 366 Figure 2: The forest plot shows the results of the MR analysis. OR: odds ratio, IVW: Inverse variance
- 367 weighted, CI: confidence interval
- 368 Figure 3: meta-analysis results

ID	Exposure	No.of SNP	Method	OR(95% CI)		Р
finn-b-O15_PREG_DM	Diabetes mellitus in pregnancy	2	IVW	1.54 (1.05 to 2.28)	•	→0.029
finn-b-GEST_DIABETES	Gestational diabetes	2	IVW	1.47 (1.03 to 2.10)		→0.035
ukb-b-16451	Gestational diabetes	17	IVW	46.06 (1.03 to 2050.78)		→0.048
ukb-a-491	Insulin using	2	IVW	12172867600.00 (358.35 to 4140000000000000000000)		0.009
ukb-b-7350	Insulin using	3	IVW	37966774513.00 (2166.45 to 6650000000000000000.00)		0.004
ukb–a–74	diabetes	25	IVW	77.28 (1.37 to 4343.59)		→0.034
finn-b-E4_DM1	Type 1 diabetes	6	IVW	1.21 (1.01 to 1.45)	•	0.036
finn-b-E4_DM1NASCOMP	Type 1 diabetes	6	IVW	1.24 (1.05 to 1.46)	 	0.010
finn-b-E4_DM1NOCOMP	Type 1 diabetes	10	IVW	1.23 (1.08 to 1.39)	——	0.002
finn-b-T1D_WIDE	Type 1 diabetes	8	IVW	1.28 (1.09 to 1.50)		0.002
finn-b-T1D_WIDE1	Type 1 diabetes	8	IVW	1.28 (1.10 to 1.48)	⊢● −−1	0.001
ebi-a-GCST007515	Type 2 diabetes	56	IVW	1.27 (1.03 to 1.56)	—	0.023
ebi-a-GCST007517	Type 2 diabetes	47	IVW	1.30 (1.06 to 1.59)		0.011
				_	1	2





Exposure Source	Cases Noncases	Odds Ratio	OR [95%—CI]	Р
Type 1 diabetes finn-b-E4_DM1	5,928 183,185		- 1.21 [1.01, 1.45]	0.04
Type 1 diabetes finn-b-E4_DM1NASCOMP	3,416 183,185		- 1.24 [1.05, 1.46]	0.01
	(010 102 105		1 0 2 51 00 1 207	0 00





